The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | CAR-T vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
Borja Puertas-Martinez, MD, University Hospital of Salamanca, Salamanca, Spain, discusses a study that aimed to compare the outcomes of patients with triple-class refractory multiple myeloma (MM) treated with CAR T-cell therapy to those treated with bispecific antibodies. Patients in the CAR-T group achieved higher response rates, however this did not translate to a greater progression-free survival (PFS) than the bispecific antibody group. Overall survival (OS) was greater in the patients treated with CAR-T. Salvage therapies used in these patients were investigated to understand the possible reasons for this. CAR-T therapy followed by bispecific antibodies resulted in the greatest survival benefit, however, Dr Puertas-Martínez highlights that data were not available to investigate whether bispecifics followed by CAR-T would result in comparable outcomes. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
